Extended Data Fig. 2: The expression and prognoses of lnc-CTHCC in cholangiocarcinoma and other types of cancer from TCGA. | Nature Cancer

Extended Data Fig. 2: The expression and prognoses of lnc-CTHCC in cholangiocarcinoma and other types of cancer from TCGA.

From: The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription

Extended Data Fig. 2

(a) The RNA levels of lnc-CTHCC in cholangiocarcinoma and paired non-tumor tissues (n = 18 patients). Data are shown as mean ± SEM. Two-tailed paired t-test was performed. (b) The RNA levels of lnc-CTHCC in tumors from HCC (n = 64 patients) and cholangiocarcinoma (n = 18 patients, P = 0.0353, two-tailed unpaired t-test). Data are shown as mean ± SEM. (c-l) Kaplan–Meier survival curves of overall survival among other types of cancer using TCGA database. Log-rank test was performed. CHOL: cholangiocarcinoma (n = 36 patients), LUAD: lung adenocarcinoma (n = 471 patients), THYM: thymoma (n = 118 patients), BRCA: breast invasive carcinoma (n = 1061 patients), OV: ovarian serous cystadenocarcinoma (n = 422 patients), COAD: colon adenocarcinoma (n = 265 patients), ESCA: esophageal carcinoma (n = 178 patients), KIRC: kidney renal clear cell carcinoma (n = 508 patients), PAAD: pancreatic adenocarcinoma (n = 178 patients), STAD: stomach adenocarcinoma (n = 379 patients). *P < 0.05.

Source data

Back to article page